Primary open angle glaucoma (broad sense), ocular hypertension
Conditions
Interventions
armA:(period1)Carteolol/LatanoprostCombination Ophthalmic
Solution given every day for two months.
(period2)Timolol/Latanoprost Combination Ophthalmic
Solution given every day for two months.
armB
Sponsors
Saito Yuta
Otsuka Pharmaceutical Co.,Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age: 20 years or older (at the time of consent obtainment) 2. Patients who have been diagnosed with POAG (broad sense) or OH for both eyes at least 6 months before (at the time of consent obtainment) 3. Patients whose IOP in the eligibility examination is as follows: between 11mmHg and 35 mmHg for one eye, less than 35 mmHg for the other eye, and within 3 mmHg of IOP differences between two eyes 4. Patients under treatment with only prostaglandin ophthalmic solution single therapy
Exclusion criteria
Exclusion criteria: Patients are excluded from participation if any of the following criteria apply. For criteria relating to the eye, patients are excluded when one eye meets any of the criteria. 1.Patients with highest corrected visual acuity of 0.2 or lower 2.Patients who are not able to discontinue the use of contact lens during the evaluation period 3.Patients who have been administered the following drugs within 28 days before the initiation of the evaluation period 4.Patients for whom new use or change of treatment drugs for glaucoma or OH is scheduled during the evaluation period 5.Patients with hypersensitivity to components of ophthalmic solution that contain carteolol hydrochloride, timolol maleate, or latanoprost 6. Patients with the following eye disorders as complications or previous history: Complications of progressive retinal disorders which impact the visual field, including diabetic retinopathy, age-related macular degeneration, and retinal detachment,Previous history or complication of acute or chronic angle-closure glaucoma 7. Patients with previous history of the following treatment 8. Patients with the following systemic disorders as complications or previous history 9. Patients who are planning to receive prohibited concomitant drugs or therapies during the evaluation period 10.Patients who have participated in post-marketing clinical trial of Carteolol/Latanoprost Combination Ophthalmic Solution 11.Patients who have participated in another clinical study within 2 months before the evaluation period and have been administered drug 12.Women who are pregnant or may be pregnant, lactating, or planning to be pregnant during the study period, or men who wishes his partner would be pregnant 13.Other patients who have been considered inappropriate as study subjects by the investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily fluctuation of intraocular pressure | — |
Contacts
Public ContactYuta Saito
Shinanozaka clinic
Outcome results
None listed